693248-53-2 Usage
General Description
3-Oxabicyclo[3.1.0]hexane-6-carboxylic acid is a chemical compound with the molecular formula C7H10O3. It is a bicyclic organic compound containing a carboxylic acid functional group. The structure of the compound consists of a six-membered ring with an oxygen atom and a carboxylic acid group attached to it. 3-Oxabicyclo[3.1.0]hexane-6-carboxylic acid is of interest to chemists and researchers due to its unique structure and potential applications in organic synthesis and medicinal chemistry. It may be used as a building block in the synthesis of more complex organic molecules or as a starting material for the development of new pharmaceuticals. Additionally, its structural features make it a useful model compound for studying the reactivity and properties of bicyclic organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 693248-53-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,9,3,2,4 and 8 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 693248-53:
(8*6)+(7*9)+(6*3)+(5*2)+(4*4)+(3*8)+(2*5)+(1*3)=192
192 % 10 = 2
So 693248-53-2 is a valid CAS Registry Number.
InChI:InChI=1/C6H8O3/c7-6(8)5-3-1-9-2-4(3)5/h3-5H,1-2H2,(H,7,8)
693248-53-2Relevant articles and documents
TGF-betaR1 inhibitor and application thereof
-
Paragraph 0849; 0854-0856, (2020/06/09)
The invention belongs to the field of medical chemistry, and particularly relates to a compound serving as a TGF-betaR1 inhibitor and application of the compound. Specifically, the invention providesa compound shown as a formula I or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the composition to treatment and/or prevention of TGF-betaR1 related diseases, such as cancers, tissue hyperplasia diseases, fibrosis and inflammatory diseases. The compound provided by the invention shows significant inhibitory activity on TGF-betaR1 kinase, and is very expected to become a therapeutic agent for TGF-betaR1 related diseases.
